Floatz Rating
C39/100
Confidence
Indicative
Sponsor
University of South Florida
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06887673CT.gov Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Montelukast (this asset) | University of South Florida | Early P1 | C · 39 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BBB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Nivolumab | InSightec | P3 | BB |
| Vorinostat | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Cyclophosphamide | Essen Biotech | P3 | BB |
| Nogitecan | Jeffrey N. Bruce | P2 | BB |
+41 more in the Brain Neoplasm cohort
Other indications for Montelukast
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Asthma | — | P4 | BBB · 73 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 73 |
| Fabry Disease | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Montelukast in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/montelukast-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →